GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 4basebio PLC (LSE:4BB) » Definitions » Institutional Ownership

4basebio (LSE:4BB) Institutional Ownership : 1.63% (As of Jun. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is 4basebio Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, 4basebio's institutional ownership is 1.63%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, 4basebio's Insider Ownership is 16.93%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, 4basebio's Float Percentage Of Total Shares Outstanding is 0.00%.


4basebio Institutional Ownership Historical Data

The historical data trend for 4basebio's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

4basebio Institutional Ownership Chart

4basebio Historical Data

The historical data trend for 4basebio can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 1.77 1.77 1.77 1.77 1.77 1.77 1.77 1.71 1.63 1.63

4basebio Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


4basebio (LSE:4BB) Business Description

Traded in Other Exchanges
Address
25 Norman Way, Over, Cambridge, GBR, CB24 5QE
4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for the effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high-purity, synthetic DNA for research, therapeutic and pharmacological use.

4basebio (LSE:4BB) Headlines

No Headlines